CLOs on the Move

Macrocure

www.macrocure.com

 
Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body`s own wound healing and regenerative components directly into the wound itself.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.macrocure.com
  • Radnor Financial Center, Suite F200 150 North Radnor Road
    Radnor, PA USA 19087
  • Phone: 201.620.6640

Executives

Name Title Contact Details

Similar Companies

QCL Quality Compliance Laboratories Inc

QCL Quality Compliance Laboratories Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Douglas Laboratories

Douglas Laboratories is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enalare Therapeutics

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.

Sovereign Pharmaceuticals

Sovereign Pharmaceuticals is your ideal CDMO partner for your pharma product development, formulation, fill/finish, packaging & commercial manufacturing needs.

Lyra Therapeutics

Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.